| Gene symbol | CD22 | Synonyms | SIGLEC-2, SIGLEC2 | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19q13.12 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | CD22 molecule | ||||
| GTO ID | GTC0987 |
| Trial ID | ChiCTR2200058606 |
| Disease | B-Cell Lymphoma |
| Altered gene | CD22 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD22 CAR-T cells |
| Phase | Early_Phase1 |
| Recruitment status | Recruiting |
| Title | Open clinical study on the safety and efficacy of immune cell therapy for adult recurrent refractory B-cell lymphoma |
| Year | 2022 |
| Country | China |
| Company sponsor | The General Hospital of Western Theater Command |
| Cohort 1 | |||||||
|
|||||||